Patients with known or suspected neuroblastoma or pheochromocytoma are eligible. 18F-DA
PET/CT scanning will not be the initial imaging study in a newly diagnosed patient.
Patients with positive findings on prior imaging within the past 4 weeks are eligible.
Prior therapy is allowed.
Patients > 1 year of age, under the care of a SJCRH physician.
Patients of both genders, and all ethnic groups, under the care of a SJCRH physician.
Female participants of childbearing age must not be lactating due to theoretical potential
harm to the infant from exposure to radiation.
Informed consent signed by participant, parent, or guardian according to the guidelines of
the institutional review board.
Inability or unwillingness of patient, parent, or guardian to consent.
Pregnancy or lactation. Future plans for pregnancy do not exclude patient participation.
Patient should not become pregnant within one month of completion of 18F-DA PET scan.
Use of medications known to interfere with 123I-mIBG uptake (principal considerations are
phenylephrine and pseudoephedrine containing compounds which need to be discontinued for 48
hours, and labetalol which needs to be discontinued for 6 weeks).
Patients less than 3 years of age who require a total length of anesthesia time greater
than 3 hours (for the FLOPET scan in conjunction with another clinical procedure requiring
sedation) will be excluded from the study.